EXTRA-PAIR PATERNITY IN GREAT TITS (PARUS MAJOR)-A LONG TERM STUDY

Behaviour ◽  
1999 ◽  
Vol 136 (9) ◽  
pp. 1157-1172 ◽  
Author(s):  
Jorg Brun ◽  
Jorg Epplen ◽  
Sabine Strohbach ◽  
Thomas Lubjuhn ◽  
Thomas Gerken

AbstractExtra-pair paternity is known to be common in many socially monogamous avian species. One question to which much attention has been paid is which benefits females might gain from copulations outside the pair bond. The 'good genes' hypothesis suggests that females obtain indirect benefits (i.e. good genes for at least part of their offspring). To test predictions from this hypothesis we analysed paternity in a study on great tits (Parus major) over 5 years. Each year 27.8-44.2% of broods contained at least one nestling that derived from a male other than its social father. 5.4-8.6% of all nestlings investigated were extra-pair sired. Males that were cuckolded survived with the same probability to the next year's breeding season as males whose broods did not contain extra-pair young. In addition there were no differences in local recruitment rates of offspring whether they were extra-pair sired or not. Our results do not fit the predictions of the 'good genes' hypothesis. Moreover, patterns of extra-pair paternity in successive years were highly inconsistent, suggesting that factors other than the genetic quality of males play an important role in determining if a particular female or male has extra-pair young in its brood.

2019 ◽  
Vol 45 (2) ◽  
pp. e90-e91
Author(s):  
M.D.L.A. Gil-Olarte Marquez ◽  
G. Gines Moreno ◽  
P. Gil-Olarte Marquez ◽  
J. Garcia Schiever ◽  
A. Gil Rendo ◽  
...  

Author(s):  
Christopher B. Cooper ◽  
Bartolome R. Celli ◽  
Robert Wise ◽  
José R. de Brito Jardim ◽  
Junhai Guo ◽  
...  

Cephalalgia ◽  
2006 ◽  
Vol 26 (10) ◽  
pp. 1203-1208 ◽  
Author(s):  
C Lampl ◽  
S Marecek ◽  
A May ◽  
L Bendtsen

This open study evaluates the effectiveness and safety of topiramate for the prophylaxis of chronic tension-type headache. Fifty-one patients were enrolled, of whom 46 completed 24 weeks of treatment with topiramate. Daily dosing was titrated from 25 mg to 100 mg by treatment week 4. The primary efficacy parameter was headache frequency at weeks 13-24 compared with baseline. Headache frequency declined from 23.50 ± 5.32 days (baseline, mean, SD) to 12.58 ± 6.28 days at weeks 13-24 ( P < 0.0001), with frequency of severe headaches dropping from 8.18 to 3.14 days ( P < 0.0001). The average headache intensity dropped from 6.13 to 2.07 on the visual analogue scale ( P < 0.0001). These parameters were not significantly reduced at weeks 5-12. A 50% reduction in headache frequency was achieved in 73% of patients at weeks 13-24. Also improved were mood, sleep, quality of life (all parameters, P < 0.0001) as well as the Beck Depression Inventory-II ( P < 0.0001). In addition, a highly significant weight loss of 2.14 kg (mean) was observed between baseline (71.64 ± 10.65 kg) and week 24 [69.50 ± 10.04 kg (SD)] ( P < 0.0001). There were only few side-effects, none of these rated severe. The results provide preliminary confirmation of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache.


2010 ◽  
Vol 90 ◽  
pp. 957
Author(s):  
S. Permpongkosol ◽  
P. Chanprasopon ◽  
C. Leenanupunth ◽  
W. Kochakarn ◽  
S. Chaimuangraj ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document